PKM and ovarian carcinoma: The available evidence supports that the contribution of RPN11/PSMD14 to ovarian cancer aggressiveness may derive from the cooperation among different mechanism, because it has been reported to decrease the enzymatic activity of pyruvate kinase M2 (PKM2).